Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;4(6):e2113739.
doi: 10.1001/jamanetworkopen.2021.13739.

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

Jean-Luc Raoul  1 , Catherine Guérin-Charbonnel  2 , Julien Edeline  3 , Victor Simmet  4 , Marine Gilabert  5 , Jean-Sébastien Frenel  1
Affiliations

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

Jean-Luc Raoul et al. JAMA Netw Open. .

Abstract

This cross-sectional study evaluates the prevalence of proton pump inhibitor use among patients with cancer at 4 French comprehensive cancer centers.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Raoul reported receiving personal fees from Bayer, Merck, and Transgene. Dr Edeline reported receiving grants from Beigene and personal fees from BMS, MSD, AstraZeneca, Roche, Bayer, Eisai, Ipsen, and Boston Scientific outside the submitted work. Dr Gilabert reported receiving personal fees from Amgen, Roche, AstraZeneca, Bayer, Merck, and Celgene. Dr Frenel reported serving on the boards of Roche, AstraZeneca, Eli Lilly, Pfizer, Daiichi, Novartis, and GSK outside the submitted work. No other disclosures were reported.

References

    1. Sharma M, Holmes HM, Mehta HB, et al. . The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155-1162. doi:10.1002/cncr.31917 - DOI - PMC - PubMed
    1. Mir O, Touati N, Lia M, et al. . Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res. 2019;25(5):1479-1485. doi:10.1158/1078-0432.CCR-18-2748 - DOI - PubMed
    1. Chu MP, Hecht JR, Slamon D, et al. . Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 2017;3(6):767-773. doi:10.1001/jamaoncol.2016.3358 - DOI - PMC - PubMed
    1. Chalabi M, Cardona A, Nagarkar DR, et al. ; imCORE Working Group of Early Career Investigators . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525-531. doi:10.1016/j.annonc.2020.01.006 - DOI - PubMed
    1. Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. Proton pump inhibitors and cancers: a hazardous association? [in French]. Bull Cancer. 2020;107(4):458-464. doi:10.1016/j.bulcan.2019.12.009 - DOI - PubMed

MeSH terms

Substances